Table 1.
Demographics for 294 subjects who initiated chemotherapy within 1 year of TMB.
| Median (Range) | |
|---|---|
| Age (years) | 60 (22–86) |
| Tumor mutational burden (mutations/megabase) |
5 (1–347) |
| |
N (%) |
| Gender | |
| Male | 142 (48%) |
| Female | 152 (52%) |
| Cancer Type | |
| Breast | 40 (14%) |
| Lung | 47 (16%) |
| Gastrointestinal | 100 (34%) |
| Other | 107 (36%) |
| Types of Chemotherapy (N) | |
| Carboplatin | 86 |
| 5-fluorouracil | 81 |
| Paclitaxel | 54 |
| Gemcitabine | 49 |
| Oxalipatin | 42 |
| Cisplatin | 35 |
| Clinical benefit* | |
| Complete response | 11 (4%) |
| Partial response | 137 (48%) |
| Stable disease≥6 months | 36 (13%) |
| Stable disease< 6 months | 24 (8%) |
| Progressive Disease | 76 (27%) |
*Patients with stable disease who were censored prior to 6 months of therapy were excluded from the clinical benefit analysis